Compare VABK & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | CABA |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.8M | 212.7M |
| IPO Year | N/A | 2019 |
| Metric | VABK | CABA |
|---|---|---|
| Price | $40.50 | $2.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 5.8K | ★ 4.0M |
| Earning Date | 01-23-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | ★ 14.22 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $56,512,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.01 | ★ N/A |
| Revenue Growth | ★ 10.39 | N/A |
| 52 Week Low | $34.12 | $0.99 |
| 52 Week High | $44.57 | $3.67 |
| Indicator | VABK | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 57.81 |
| Support Level | $39.10 | $2.04 |
| Resistance Level | $40.43 | $3.34 |
| Average True Range (ATR) | 0.63 | 0.22 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 65.12 | 54.23 |
Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.